Holmusk builds an evidence platform with behavioral health combining behavioral health databases with artificial intelligence (AI) powered analytics and digital solutions. Its technology powers data-driven medicine that uses analytic and digital tools to address the need in healthcare and pharma-life science. The company was founded in 2015 and is based in Singapore, Singapore.
Holmusk's Product Videos
ESPs containing Holmusk
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The behavioral health electronic health records (EHR) market is a rapidly changing field of neuropsychiatry that aims to address the unique needs of patients with mental health conditions. It is challenging to objectively assess disease severity and treatment progress in psychiatric disorders as they lack quantitative biomarkers, objective outcome metrics, and randomized clinical trials are not re…
Holmusk's Products & Differentiators
The NeuroBlu database serves as the healthcare and pharmaceutical industry’s leading source for real-world behavioral health data. The database contains de-identified, longitudinal EHR data from over 1 million patients collected over more than 20 years from geographically diverse clinics across the U.S. The rapidly growing database includes data on patient diagnosis, treatment, hospitalization, and demographics, as well as nuanced information about external stressors, progress, treatment side effects, and more. NeuroBlu data fuel research for behavioral health conditions such as major depressive disorder, bipolar disorder, PTSD, ADHD, schizophrenia, substance-related disorders, and many others. The data have been used for a range of purposes, from assisting with early-stage drug research to driving public health impact.
Research containing Holmusk
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Holmusk in 5 CB Insights research briefs, most recently on Mar 8, 2023.
Expert Collections containing Holmusk
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Holmusk is included in 2 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Latest Holmusk News
Sep 1, 2023
Patrick J. Kennedy, former U.S. Representative, and Nawal Roy, founder and CEO of Holmusk, discuss how the pair is using experience and data to create a policy guide for lawmakers. Share Former U.S. Representative Patrick J. Kennedy, founder of the Kennedy Forum, and Nawal Roy, founder and CEO of Holmusk Photo courtesy of Patrick J. Kennedy/Holmusk In part two of our two-part series, Patrick J. Kennedy, former U.S. Representative and founder of The Kennedy Forum, and Nawal Roy, CEO and founder of global behavioral health data platform Holmusk, discuss with MobiHealthNews how coverage for mental health has changed since the signing of the parity act and what steps the partners are taking to help lawmakers draft even more effective bills to progress mental healthcare coverage. MobiHealthNews: Mr. Kennedy, since the Mental Health Parity and Addiction Equity Act became law, how have you seen insurance coverage for behavioral health change? Patrick J. Kennedy: Yeah, so we're dealing with a legacy of discrimination for a long, long time where mental health has been carved out. It has been marginalized. People were charged higher co-pays, higher deductibles, higher premiums and they were really subjected to lower lifetime caps for coverage. All of those things we eliminated when we passed the parity law. And what we also did was say that you couldn't impose any higher medical management decision thresholds for gaining access to mental health and addiction then you would otherwise see in medical management for other medical services. That has been harder to manage in terms of its enforcement, largely because regulators are not equipped to really hold insurance companies accountable because they have big departments, and they can shower regulators with these massive amounts of data and check all these boxes and there's no way to validate and verify. That's changing under new proposals that have been put out. There will be a greater burden of proof on the part of payers to do a lot of that analysis and demonstrate their, you know, fidelity to parity through the paperwork that they submit. We've made more progress in some states than others because they have a stronger regulatory infrastructure. California, New York, Massachusetts and Pennsylvania have had much stronger enforcement of their state parity laws. We obviously are very concerned about the Wit Decision in Northern California because it has broader implications about whether payers must follow generally accepted standards of care, medical standards of care, or whether insurance companies can often continue to develop their own criteria for making those decisions on what level of care you get, how long that care is. Nawal Roy: Let me add to what Patrick just said on two or three points. Point number one is we can certainly learn from other therapeutic areas because the progress in behavioral health has been substandard even after Patrick really lead the signing of the parity act. The total cost that we as a society are spending is significantly larger than purely on the healthcare expense. And the drivers behind that can be we don't expect fundamentally insurance companies to change on their own. Either they feel the pressure of the market forces, or the pressure of the litigation, or the pressure of the regulation. So the burden is on us to figure out who is going to be the first moving this. Any insurance company can take this and literally say, I'm going to make the changes and make this as a source of my competitive advantage and start covering it. If that happens, then all of a sudden, other companies will start doing it. The second could be literally a regulation driving and saying no, parity is very important. So it is a hardcore sort of social/policy/clinical problem, and at the core of all of it is, if you really want to go into solving the plumbing of it, is all around data. How do we connect the dots through a common language of understanding the data so that we can have this clinical discussion but also can have policy discussions in a very meaningful fashion? Kennedy: We have to understand, as Nawal said, the distributed cost of not investing in mental health. If we capture the downstream costs of not providing the upfront care, it will be easier for us to justify more upfront care, a greater investment in mental health, but it's not going to be until we really understand the full impact of untreated mental health on cardiovascular disease, on oncology, on diabetes, then we're going to be able to justify asking for a much bigger percentage of the premium dollar go into mental health. Power really doesn't change easily and moving dollars from one section of the healthcare system to another is going to be very difficult. But if the data is clear, that if you want better outcomes for heart disease and diabetes, and so forth, that mental health is the secret sauce that's going to deliver that then it'll be easier for us to make that case. MHN: What are the next steps? Kennedy: We are organizing what's known as the Alignment for Progress , which is a five-year campaign to put forth, for the first time ever, a policy guide that will include all of the mental health diagnoses, all the addiction diagnoses, all behind one policy guide in electronic form that will assist policymakers in writing better policy and lawmakers writing better laws and regulators writing better regulations. We are doing this in collaboration with all of the major stakeholders in mental health and addiction. And I have the unique ability to bring them together because parity is uniquely beneficial to all of them. And because of my experience in policy, I can kind of take this on as kind of a quarterback because, frankly, none of the individual stakeholders can necessarily convene the others in the same way that I'm able to convene them. And I'm using the 15th anniversary of the parity law being signed by George W. Bush and the 60th anniversary of President Kennedy's Community Mental Health Act to initiate this campaign. We're going to release a policy guide that we've worked on with some very big stakeholders in this space. And what I'm very excited about is we're trying to create the equivalent of a chamber of commerce agenda for businesses or an AFL-CIO for labor organizations. We need to create something akin to that for mental health and addiction, where we look at these issues holistically because the same things that help, you know, a person with addiction help people with mental illness and vice versa. We have 98% in common, but we often, unfortunately, advocate within silos. And I really believe that Nawal is going to be a crucial partner with Holmusk for us in the private sector to help inform how data can really influence better decision-making. And frankly, a lot of other stakeholders are going to benefit from this. I mean, because if we want value-based contracting, we're going to need to really understand the risk of various populations so that people will invest in the proposition that if we do a better job and build a better mousetrap and get better outcomes, that is worthwhile. We're only going to be able to do that if we can demonstrate that value can be brought in terms of better outcomes for patients and the lowering of their comorbidities. The lowering of their symptoms, and, in turn, the lowering of the cost not only to insurers but lowering the cost to society. That's our big holy grail for the long haul. Tags:
Holmusk Frequently Asked Questions (FAQ)
When was Holmusk founded?
Holmusk was founded in 2015.
Where is Holmusk's headquarters?
Holmusk's headquarters is located at 71 Ayer Rajah Crescent, Singapore.
What is Holmusk's latest funding round?
Holmusk's latest funding round is Series B.
How much did Holmusk raise?
Holmusk raised a total of $76.3M.
Who are the investors of Holmusk?
Investors of Holmusk include Heritas Capital, Health Catalyst Capital Management, dRx Capital, Northwell Holdings & Ventures, Optum Ventures and 6 more.
Who are Holmusk's competitors?
Competitors of Holmusk include NeuroFlow, Feel Therapeutics, Komodo Health, Tempus, Owkin and 11 more.
What products does Holmusk offer?
Holmusk's products include NeuroBlu Database and 1 more.
Compare Holmusk to Competitors
Evidation operates as a multichannel health tracking platform. It enables users to connect with multiple appications to track everyday activity and earn rewards for steps, sleep, surveys, and more. The company was founded in 2012 and is based in San Mateo, California.
Aetion is a healthcare analytics company. It provides decision-grade real-world evidence solutions to biopharma companies, payers, and regulatory agencies. It offers a platform that analyzes data from the real world to produce scientifically validated answers on treatments, effectiveness, and value. The company was founded in 2012 and is based in New York, New York.
Syapse develops software for aggregating and structuring biomedical data. It combines data intelligence, insight analytics and applied experience through healthcare organizations looking to transform patients’ lives using real-world evidence. The company was founded in 2008 and is based in San Francisco, California.
nference makes biomedical knowledge computable to solve urgent healthcare problems of biopharmas and medical centers. The company offers EMR data, software products and services, record de-identification, curation of unstructured information, and data creation via digitization of pathology and molecular sequencing. It was founded in 2013 and is based in Cambridge, Massachusetts.
Verantos provides high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, AI technology, and measured validity, Verantos generates research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use. The company was founded in 2015 and is based in Menlo Park, California.
Huma offers an intelligent software solution to combine predictive algorithms, artificial intelligence (AI), digital biomarkers, and data from patients. It remotely monitors patient indicators and assists researchers and pharmaceutical companies in conducting decentralized clinical trials. It combines digital biomarkers and predictive algorithms to offer a blend of medical expertise with several leading healthcare institutes. It was formerly known as Medopad. The company was founded in 2011 and is based in London, United Kingdom.